Project Navigator
Let's try to finance it!
A new, user friendly way, to get information about current clinical trials available to prostate cancer patients.
Tags
177Lu-PSMA-617 225Ac abiraterone abiraterone acetate ADC ai in healthcare antibody-drug conjugate apalutamide ATM B7-H3 bispecific antibody bone metastases bone metastasis BRCA BRCA2 cancer immunotherapy CAR-T CD3 clinical trial crispr darolutamide docetaxel drug repurposing enzalutamide EZH2 inhibitor HRR immunotherapy mcrpc metastatic hormone-sensitive prostate cancer mHSPC mRNA NEPC neuroendocrine prostate cancer oncolytic virus PARP1 PARP inhibitor Pluvicto prostate cancer protac PSMA radioligand therapy radiopharmaceuticals real-world data STEAP1 T-cell therapy
Latest Posts
- Killing the Last 0.1%: Targeting Cancer Persister Cells June 15, 2026
- Phase III PrTK03 Trial Results: Aglatimagene Besadenovec (CAN-2409) Improves Survival in Localized Prostate Cancer June 15, 2026
- Newsletter 24/2026 June 14, 2026
- Phase 2 Trial for 61Cu-NU101 vs 18F-Piflufolastat in Metastatic Prostate Cancer June 11, 2026

Phase 1 Trial of a Triple Combination: 177Lu-PSMA-I&T, Olaparib, and Pembrolizumab
/in Clinical Trial, Metastatic, Phase 1/by MaxLYA914: A Novel Oral PROTAC Targeting Androgen Receptor Variants in Prostate Cancer
/in Preclinical Research, PROTACs/by MaxPhase 1/2 Trial for DS-3939a: A Novel TA-MUC1–Directed ADC for Advanced Prostate Cancer and Beyond
/in Clinical Trial, Metastatic, Phase 1, Phase 2/by MaxAI Platform Aims to Revolutionize Cancer Immunotherapy
/in Artificial Intelligence, Immunotherapy, Preclinical Research/by MaxA new AI platform developed by researchers at the Technical University of Denmark and the Scripps Research Institute has dramatically accelerated the design of specialized protein molecules called “minibinders” to enhance cancer immunotherapy. Normally, T cells recognize cancer cells by detecting protein fragments (peptides) presented on their surface by molecules known as pMHCs, but harnessing […]
FDA Clears First-in-Human Phase 1 Trial: RV-01 Targeting Solid Tumors
/in Clinical Trial, Metastatic, Phase 1/by MaxPhase 1 Trial For BL-M14D1 For Neuroendocrine Cancers
/in Clinical Trial, Metastatic, Phase 1/by MaxNew Immunotherapy Strategy Aims to Turn All Solid Tumors Into Immune Targets
/in Immunotherapy, Preclinical Research/by MaxScientists Trace Deadly Shift in Prostate Cancer to Two Key Genes
/in Preclinical Research/by Max